SXTP

Business Context and Reporting Period

Company: 60 Degrees Pharmaceuticals, Inc. (SXTP)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: A specialty pharmaceutical company focused on infectious diseases, primarily commercializing Arakoda (tafenoquine) for malaria prevention. The company is an emerging growth company and smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Composition: Product revenues increased 106% quarter-over-quarter (QoQ) and 40% year-over-year (YoY) for the six-month period. This increase was driven by higher shipments to a third-party logistics (3PL) partner to build channel inventory, rather than a proportional increase in sell-through to end customers. Research revenues dropped to $0 as the USAMMDA contract concluded in late 2025.
• Gross Margin Compression: Gross margin decreased to 27.32% (QoQ) and 35.99% (YoY six-month) from 50.41% and 53.37% respectively. This decline is attributed to the cessation of selling lower-cost imported Kodatef in the U.S. and higher costs associated with new Arakoda lots, including yield losses and packaging.
• Operating Expenses: R&D expenses increased 158% QoQ and 46% YoY (six-month), primarily due to the activation of three Babesiosis trials. G&A expenses increased 6% QoQ and 8% YoY (six-month), driven by higher sales and marketing costs.
• Derivative Liability Impact: The loss from the change in fair value of derivative liabilities decreased significantly to $5,665 (QoQ) and $10,232 (six-month) compared to $140,447 and $135,342 in the prior year periods, reducing the non-cash drag on net loss.

Guidance, Outlook, and Risks

• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for one year from the filing date. Based on current projections and recent financing (including a July 2026 PIPE offering), the company estimates sufficient funds only through early-October 2026.
• Liquidity Strategy: The company plans to fund operations through additional equity financings, debt, or business development transactions. It recently exhausted its capacity under its At-The-Market (ATM) agreement due to stock price declines and Form S-3 limitations.
• Regulatory and Operational Risks:
  • FDA Objection: The FDA objected to marketing Australian Chestnut Extract as a dietary supplement in May 2026.
  • Nasdaq Compliance: The company recently executed a 1:4 reverse stock split to regain compliance with Nasdaq's minimum bid price rule. It remains at risk of delisting if stockholders' equity falls below $2.5 million or if it fails to maintain the minimum bid price.
  • Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, including inadequate policy design and lack of documentation, which remain unremediated.
• Contingent Obligations: A $10 million contingent milestone payment to Knight Therapeutics remains a derivative liability, payable upon a sale of Arakoda or a Change of Control.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $1.02 million cash balance against the stated burn rate and the timeline to October 2026.
• Revenue Quality: Distinguish between revenue recognized from channel inventory builds (3PL shipments) versus actual sell-through to pharmacies to assess sustainable demand.
• Financing Capability: Assess the feasibility of raising additional capital given the current stock price, the exhaustion of the ATM facility, and the "Going Concern" warning.
• Internal Controls: Review the status of remediation efforts for the material weaknesses in financial reporting controls.
• Product Pipeline: Monitor the progress and costs of the Babesiosis clinical trials, which are driving the increase in R&D expenses.